Sushrit Pasumarthy
I am currently evaluating the efficacy of PD-L1 overexpression in genetically engineered breast cancer cells as a strategy to impede T-cell infiltration into immunogenic cancers and directly inhibit T-cell function. This will serve as a model to evaluate the utility of the broader focus of the research project I am a part of, which is to investigate the potential therapeutic role of PD-L1 as an immunosuppressive agent in preventing immune rejection after heart transplantation.